Evidence map›Paper›PMID 38290969›Full record

ArticleTrends in cancer2024

Benefits and opportunities of the transgenic Oncopig cancer model.

Kirtan Joshi, Bhanu P Telugu, Randall S Prather, Jeffrey N Bryan, Timothy J Hoffman, Jussuf T Kaifi, Satyanarayana Rachagani

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Trends in cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Kirtan JoshiDepartment of Medicine, Division of Hematology & Medical Oncology, University of Missouri, Columbia, MO, USA; Department of Surgery, Section for Thoracic Surgery, University of Missouri, Columbia, MO, USA; Roy Blunt NextGen Precision Health Institute, University of Missouri, Columbia, MO, USA.
Bhanu P TeluguNational Swine Resource and Research Center, Division of Animal Sciences, University of Missouri, Columbia, MO, USA.
Randall S PratherNational Swine Resource and Research Center, Division of Animal Sciences, University of Missouri, Columbia, MO, USA.
Jeffrey N BryanDepartment of Veterinary Medicine and Surgery, University of Missouri, Columbia, MO, USA; Ellis Fischel Cancer Center, University of Missouri, Columbia, MO, USA.
Timothy J HoffmanDepartment of Medicine, Division of Hematology & Medical Oncology, University of Missouri, Columbia, MO, USA.
Jussuf T KaifiDepartment of Surgery, Section for Thoracic Surgery, University of Missouri, Columbia, MO, USA; Roy Blunt NextGen Precision Health Institute, University of Missouri, Columbia, MO, USA; Ellis Fischel Cancer Center, University of Missouri, Columbia, MO, USA; MU Institute for Data Science and Informatics, University of Missouri, Columbia, MO, USA; Siteman Cancer Center, Washington University, St. Louis, MO, USA. Electronic address: kaifij@health.missouri.edu.
Satyanarayana RachaganiRoy Blunt NextGen Precision Health Institute, University of Missouri, Columbia, MO, USA; Department of Veterinary Medicine and Surgery, University of Missouri, Columbia, MO, USA; Ellis Fischel Cancer Center, University of Missouri, Columbia, MO, USA. Electronic address: srachagani@missouri.edu.

Funding

Resource Core for National Swine Resource and Research Center (NSRRC) Years 21-25U42OD011140 · OD · UNIVERSITY OF MISSOURI-COLUMBIA · PI Kiho Lee, Kevin Dale Wells · 2012 to 2026
$26.7M
Targeting tumor and its microenvironment using nanotherapeutics for pancreatic cancerR01CA247763 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI RACHAGANI, SATYANARAYANA · 2020 to 2024
$1.9M
NCI NIH HHS R01 CA247763NIH HHS U42 OD011140
6 · The paper itself

Abstract

Cancer remains a leading cause of morbidity and mortality, and a paradigm shift is needed to fundamentally revisit drug development efforts. Pigs share close similarities to humans and may serve as an alternative model. Recently, a transgenic 'Oncopig' line has been generated to induce solid tumors with organ specificity, opening the potential of Oncopigs as a platform for developing novel therapeutic regimens.

Indexed as

NeoplasmsAnimalsAnimals, Genetically ModifiedDisease Models, AnimalHumansSwinelarge animal cancer modelOncopigporcine cancer modeltransgenic cancer modeltranslational cancer research

Identifiers

PMID38290969
PMCPMC10939816

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.